Neutrophils as critical orchestrators of chronic inflammation
Cellular & Molecular Immunology, Published online: 13 January 2026; doi:10.1038/s41423-025-01380-wNeutrophils as critical orchestrators of chronic inflammation
Cellular & Molecular Immunology, Published online: 13 January 2026; doi:10.1038/s41423-025-01380-wNeutrophils as critical orchestrators of chronic inflammation
Cellular & Molecular Immunology, Published online: 09 January 2026; doi:10.1038/s41423-025-01381-9Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic ma…
Cellular & Molecular Immunology, Published online: 06 January 2026; doi:10.1038/s41423-025-01384-6Epigenetics control lineage decisions during hematopoiesis of innate lymphocytes
Cellular & Molecular Immunology, Published online: 06 January 2026; doi:10.1038/s41423-025-01382-8Prion-like MAVS fibrils stitch mitochondria to promote a rapid antiviral response
Cellular & Molecular Immunology, Published online: 06 January 2026; doi:10.1038/s41423-025-01372-wFrom splicing noise to therapeutic signaling: RCAN1–4 as a neoepitope in glioblastoma
Cellular & Molecular Immunology, Published online: 06 January 2026; doi:10.1038/s41423-025-01377-5The multilayered identity of B cell memory
Cellular & Molecular Immunology, Published online: 01 January 2026; doi:10.1038/s41423-025-01352-0MDA5 regulates BCR signaling and B-cell function via NF-κB-mediated DNM1
Cellular & Molecular Immunology, Published online: 24 December 2025; doi:10.1038/s41423-025-01376-6CD160+ intraepithelial lymphocytes and CCRL2+ macrophages drive differential repair in cardiac and liver injuries
Cellular & Molecular Immunology, Published online: 23 December 2025; doi:10.1038/s41423-025-01360-0C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma
Cellular & Molecular Immunology, Published online: 19 December 2025; doi:10.1038/s41423-025-01378-4Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy